Increases in cardiac troponin-I, indicative of myocardial injury, are common and prognostic in COVID-19. • Troponin-I elevation is an accurate predictor of mortality in hospitalized patients with COVID-19. • A normal cardiac troponin-I level on admission has a very high negative predictive value for all-cause in-hospital mortality. • A normal cardiac troponin-I level on admission is a very strong and independent indicator of hospital survival. • Cardiac troponin-I may facilitate COVID-19 stage classification and risk-stratification.

Multiple metrics like SOFA score, APACHE II, AND SAPS III have been validated to predict mortality in critically ill patients. However, there is limited data about the applicability and validation of the SOFA score in critically ill patients with COVID-19 METHODS: This is a retrospective cohort study aimed to evaluate and validate the applicability of SOFA score in critically ill patients with COVID 19. SARS-CoV-2 was diagnosed via PCR, and full SOFA score (6 system variables) was performed on days 1, 3 and 5 of critical care admissions with estimation of standard variation

No abstract

:Early during the Coronavirus disease 2019 (Covid-19) pandemic, concerns were raised regarding potential adverse outcomes in patients taking angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs). These concerns were based on animal studies showing increased ACE-2 expression in mice treated with ACEI/ARB. This is a single-center, retrospective, cohort study of 289 patients diagnosed with 2019 Novel Coronavirus (SARS-CoV-2) hospitalized between March of 2020 and June of 2020. The study was intended to investigate the impact of ACEIs and/or ARBs on in-hospital mortality, intensive care unit (ICU) admission, postadmission hemodialysis requirement, and the need for mechanical ventilation in patients with COVID-19. This cohort of 289 patients included 139 of 289 women (48%) with a mean age of 61 ± 19 years. Patients using ACEIs/ARBs were older (69.68 vs. 57.9 years; P < 0.0001), more likely to have a history of hypertension (97% vs. 36%; P < 0.0001), diabetes mellitus (48% vs. 20.9%; P < 0.0001), chronic heart failure (11.39% vs. 4.29%; P < 0.0512), coronary artery disease (20.25% vs. 7.14%; P < 0.0025), stroke/Transient Ischemic Attack (7.59% vs. 2.38%; P < 0.0761), chronic kidney disease (11.39% vs. 3.33%; P < 0.0167), atrial fibrillation/flutter (18.99% vs. 7.14%; P < 0.0080), and dementia (22.7% vs. 11.4%; P < 0.0233) compared with the nonuser group. There was significantly higher in-hospital mortality in patients using ACEIs/ARBs than nonusers, respectively (32.9% vs. 15.2%; P < 0.0015). However, a multivariate logistics regression analysis performed to adjust for common confounders demonstrated no significant difference in all-cause in-patient mortality (P 0.7141). Admission to ICU, postadmission hemodialysis requirement, and mechanical ventilation showed no significant differences between the 2 groups (P = NS). This study suggests that the use of ACEIs and ARBs in patients with COVID-19 was not found to significantly increase all-cause in-hospital mortality, ICU admissions, and hemodialysis and mechanical ventilation requirements.